Pharmacological Modulation of Vagal Nerve Activity in Cardiovascular Diseases / 神经科学通报·英文版
Neuroscience Bulletin
;
(6): 156-166, 2019.
Article
in English
| WPRIM
| ID: wpr-775475
ABSTRACT
Cardiovascular diseases are life-threatening illnesses with high morbidity and mortality. Suppressed vagal (parasympathetic) activity and increased sympathetic activity are involved in these diseases. Currently, pharmacological interventions primarily aim to inhibit over-excitation of sympathetic nerves, while vagal modulation has been largely neglected. Many studies have demonstrated that increased vagal activity reduces cardiovascular risk factors in both animal models and human patients. Therefore, the improvement of vagal activity may be an alternate approach for the treatment of cardiovascular diseases. However, drugs used for vagus nerve activation in cardiovascular diseases are limited in the clinic. In this review, we provide an overview of the potential drug targets for modulating vagal nerve activation, including muscarinic, and β-adrenergic receptors. In addition, vagomimetic drugs (such as choline, acetylcholine, and pyridostigmine) and the mechanism underlying their cardiovascular protective effects are also discussed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Sympathetic Nervous System
/
Vagus Nerve
/
Cardiovascular Diseases
/
Acetylcholine
/
Receptors, Muscarinic
/
Cholinergic Agents
/
Therapeutic Uses
/
Drug Therapy
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Neuroscience Bulletin
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS